Search Results
Mar 24, 2026, 09:00 ET NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable
More news about: NeuroSense
Mar 24, 2026, 08:00 ET Argo Biopharma Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026
March 24, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, is proud to have been named to Fast Company's list of the World's Most Innovative Companies of 2026. This year's list highlights
More news about: Argo Biopharmaceutical Co., Ltd
Mar 24, 2026, 07:57 ET RYBODYN ANNOUNCES SEED FINANCING TO ADVANCE AI-DRIVEN DISCOVERY OF HIDDEN CANCER TARGETS
more than 3 million conserved, novel dark (previously not characterized) RNAs, while increasing the number of cryptic peptides encoded by these dark RNA species by over two orders of magnitude. Taken together, the CypherAtlas™ database now contains more than 80,000 cryptic peptides identified empirically
More news about: RyboDyn
Mar 23, 2026, 08:30 ET Fast-Tracking IVT mRNA Candidate Selection Through Smarter RNA Design, Upcoming Webinar Hosted by Xtalks
integrated in vitro transcribed (IVT) RNA and RNA-lipid nanoparticle (LNP) workflows can help move RNA discovery programs from construct design to actionable data with greater speed and confidence. Dr. Shambhavi Shubham will discuss parallel screening of RNA constructs and LNP formulations, expression
More news about: Xtalks
Mar 23, 2026, 07:24 ET Interna Therapeutics Announces Human Challenge Trial Agreement with the University of Oxford to Advance Intranasal MNM-siRNA SARS-CoV-2 Prophylaxis Program
vaccinology. "This collaboration with Oxford University and the support of the Gates Foundation mark a defining moment for the company and for the field of RNA therapeutics," said Yuval Gottenstein, Chief Executive Officer of Interna Therapeutics. "For the first time, we have the opportunity to demonstrate in
More news about: Interna Therapeutics
Mar 23, 2026, 07:00 ET Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe,
More news about: Insmed Incorporated
Mar 20, 2026, 08:00 ET Co-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Mar 20, 2026, 07:35 ET Mit RiboPepSTAR™ geht Ribo über die Leber hinaus - und ermöglicht so den gezielten Transport von siRNA in verschiedene Organe
Suzhou Ribo Life Science Co., Ltd. („Ribo" oder „das Unternehmen", Börsenkürzel an der Hongkonger Börse: 6938) war eingeladen worden, am 19. März auf der RNA Leaders Europe Conference in Wien, Österreich, einer der führenden Konferenzen zum Thema Oligonukleotide, einen Vortrag zu halten.
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 20, 2026, 07:32 ET Avec RiboPepSTAR™, Ribo permet l'administration ciblée de petits ARN interférents (pARNi) à plusieurs organes autres que le foie
Life Science Co., Ltd.(« Ribo » ou « la société », code de la Bourse de Hong Kong : 6938) a été invitée à prononcer un discours lors de la conférence « RNA Leaders Europe » (conférence européenne des leaders de l'ARN), l'une des principales conférences sur les oligonucléotides, le 19 mars à Vienne, en Autriche.
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 20, 2026, 07:29 ET Ribo amplía su alcance más allá del hígado con RiboPepSTAR™
Life Science Co., Ltd. ("Ribo" o "la Compañía", Código Hong Kong Stock Exchange: 6938) había sido invitada a dar una conferencia en la Conferencia RNA Leaders Europe en Viena, Austria, el 19 de marzo, una de las conferencias más importantes sobre oligonucleótidos.
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 20, 2026, 03:18 ET Ribo expands beyond the liver with RiboPepSTAR™ - enabling targeted siRNA delivery to multiple organs
/PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) had been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 20, 2026, 02:41 ET Ribo expands beyond the liver with RiboPepSTAR™ - enabling targeted siRNA delivery to multiple organs
/PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) had been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 19, 2026, 08:10 ET Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer
TherapeuticsRactigen Therapeutics is a clinical-stage biopharmaceutical company innovating next-generation RNA therapeutics, with a primary focus on small activating RNAs (saRNAs) developed through its clinically validated RNA activation (RNAa) technology. Leveraging proprietary delivery platforms such as SCAD™, LiCO™,
More news about: Ractigen Therapeutics
Mar 18, 2026, 15:43 ET Genome Canada and Ontario Genomics Award Specific Biologics and Western University $1.8 Million Grant to Develop a Machine Learning Platform to Accelerate the Development of the Company's Dualase®-based Therapeutics
the seamless removal, repair, or insertion of both small and large DNA sequences, offering broad therapeutic potential, coupled with single AAV or all-RNA delivery. Dualase® achieves best-in-class accurate editing efficiency with undetectable off-target effects as demonstrated in preclinical
More news about: Specific Biologics Inc.
Mar 18, 2026, 15:43 ET Genome Canada and Ontario Genomics Award Specific Biologics and Western University $1.8 Million Grant to Develop a Machine Learning Platform to Accelerate the Development of the Company's Dualase®-based Therapeutics
the seamless removal, repair, or insertion of both small and large DNA sequences, offering broad therapeutic potential, coupled with single AAV or all-RNA delivery. Dualase® achieves best-in-class accurate editing efficiency with undetectable off-target effects as demonstrated in preclinical
More news about: Specific Biologics Inc.
Mar 18, 2026, 11:32 ET MGI Tech en Predica Diagnostics versnellen screening op baarmoederhalskanker op DNBSEQ-platforms
waarna wereldwijde uitbreiding volgt.Over Predica DiagnosticsPredica Diagnostics B.V. is een precisie-oncologiebedrijf dat gerichte RNA-sequencingtests ontwikkelt voor vroege kankerdetectie, risicostratificatie en begeleiding tijdens de behandeling. Predica is opgericht als spin-off van
More news about: MGI Tech Co., Ltd.
Mar 18, 2026, 10:44 ET /C O R R E C T I O N -- NeuroSense/
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable
More news about: NeuroSense
Mar 18, 2026, 10:00 ET New England Biolabs® releases EnClose™ Cell-free dbDNA™ Synthesis Kit in collaboration with Touchlight to accelerate DNA and RNA therapeutic development
to larger-scale manufacturing."This dbDNA synthesis kit aligns with NEB's overarching commitment to support and streamline the development of RNA- and DNA- based therapies. By providing a direct entry into the nucleic acid therapeutic space with a scalable, cell-free template solution, NEB continues
More news about: New England Biolabs, Inc.
Mar 18, 2026, 07:45 ET Singular Genomics and Vanderbilt University Medical Center Establish Center of Excellence to Advance High-Throughput Spatial Multimodal Profiling in Gastric Pre-Cancer
for 3D atlas-building workflows.G4X is designed to generate integrated in situ readouts at scale, combining 1,000-plex RNA, 18-plex protein, and fH&E at subcellular resolution from each FFPE tissue section at industry-leading throughput.Supporting
More news about: Singular Genomics
Mar 18, 2026, 07:44 ET Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
Type: Poster Session: Experimental and Molecular Therapeutics: RNA, Gene and Cell Therapies, and Enabling Assay Technologies Date/Time: April 19,
More news about: Jazz Pharmaceuticals plc
Mar 18, 2026, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
and is highly effective in preclinical studies"Session Category: Experimental and Molecular TherapeuticsSession Title: RNA, Gene and Cell Therapies, and Enabling Assay TechnologiesSession Date and Time: April 19, 2026 from 2-5 p.m. PTLocation:
More news about: Genprex, Inc.
Mar 18, 2026, 06:50 ET Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
unmet need in uncontrolled gout with a potential best–in–class therapy. We are also sharpening our focus on rare renal diseases with PRX–119 and our RNA–based discovery collaboration with Secarna, leveraging the capabilities of our ProCellEx® platform. As we enter 2026, we remain committed
More news about: Protalix BioTherapeutics, Inc.
Mar 17, 2026, 22:34 ET Ribo präsentiert auf der RNA Leaders Europe Conference Daten zur extrahepatischen Wirkstoffabgabe
-- Suzhou Ribo Life Science Co., Ltd. („Ribo" oder „das Unternehmen", Börsenkürzel an der Hongkonger Börse: 6938) wurde eingeladen, am 19. März auf der RNA Leaders Europe Conference in Wien, Österreich, einen Vortrag zu halten, einer der führenden Konferenzen im Bereich Oligonukleotide.
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 17, 2026, 22:32 ET Ribo présentera des données sur l'administration extra-hépatique lors de la conférence RNA Leaders Europe
Life Science Co., Ltd. (« Ribo » ou « la Société », code de la Bourse de Hong Kong : 6938) a été invitée à prononcer un discours lors de la conférence RNA Leaders Europe, l'une des principales conférences sur les oligonucléotides qui se tiendra à Vienne, en Autriche, le 19 mars.
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 17, 2026, 21:26 ET Innorna gibt die Genehmigung des IND-Antrags für IN026 durch die FDA bekannt und treibt damit die Entwicklung von mRNA-basierten Therapien für chronische Stoffwechselerkrankungen voran
Massachusetts, 18. März 2026 /PRNewswire/ -- Innorna, ein Biotechnologieunternehmen im klinischen Stadium, das RNA-Medikamente entwickelt, gab heute bekannt, dass die US-amerikanische Arzneimittelbehörde FDA (Food and Drug Administration) seinen Antrag auf Zulassung
More news about: Innorna Co., Ltd.